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The genotype-phenotype correlation ofMEFV remains unclear for the familial Mediterra-
nean fever (FMF) patients, especially without canonicalMEFVmutations in exon 10. The
risk of FMF appeared to be under the influence of other factors in this case. The contribution
of HLA polymorphisms to the risk of FMF was examined as strong candidates of modifier
genes.
Methods
Genotypes of HLA-B and -DRB1 loci were determined for 258 mutually unrelated Japanese
FMF patients, who satisfied modified Tel-Hashomer criteria, and 299 healthy controls. The
effects of carrier status were evaluated for the risk of FMF by odds ratio (OR). The HLA ef-
fects were also assessed for clinical forms of FMF, subsets of FMF with certainMEFV geno-
types and responsiveness to colchicine treatment.
Results
The carriers of B*39:01 were increased in the patients (OR = 3.25, p = 0.0012), whereas
those of DRB1*15:02 were decreased (OR = 0.45, p = 0.00050), satisfying Bonferroni’s
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correction for multiple statistical tests (n = 28, p<0.00179). The protective effect of
DRB1*15:02 was completely disappeared in the co-existence of B*40:01. The HLA effects
were generally augmented in the patients without a canonicalMEFV variant allele M694I, in
accordance with the notion that the lower penetrance of the mutations is owing to the larger
contribution of modifier genes in the pathogenesis, with a few exceptions. Further, 42.9% of
14 colchicine-resistant patients and 13.5% of 156 colchicine-responders possessed
B*35:01 allele, giving OR of 4.82 (p = 0.0041).
Conclusions
The differential effects of HLA class I and class II polymorphisms were identified for Japa-
nese FMF even in those with high-penetranceMEFVmutations.
Introduction
Familial Mediterranean fever (FMF) has been considered to be an autosomal recessive trait
which is characterized by self-limiting recurrent fever and serositis (OMIM #249100),[1] and
categorized to an autoinflammatory disease.[2]MEFV, which was identified as the responsible
gene for FMF, encodes cytosolic protein pyrin (also known as marenostrin) which regulates
the activity of NLRP3 inflammasome.[3] Two hundred and ninety six sequence variants in
MEFV gene have been registered to “Infevers” database (http://fmf.igh.cnrs.fr/ISSAID/
infevers/) as of September 1st, 2014, including hot spots for pathogenic amino acid substitu-
tions in the C-terminus region of the protein. Recently, dominant form (OMIM #134610) of
the disease was reported,[4] and overlapping and continuum to other autoinflammatory dis-
eases were proposed.[5] We performed a nation-wide surveillance of FMF in Japan and found
that only M694I is commonly identified among hot spot mutations in the exon 10, homozy-
gotes of which comprise as many as 10% of Japanese FMF.[6] We also noticed that more than
one third of the patients did not carry two copies of pathological mutations in theirMEFV
gene.[6] It is possible that the indistinct genotype-phenotype correlation observed in Japanese
FMF is owing to the effect of modifier genes. Genes in the HLA region are candidates for the
modifier genes because they are involved in various inflammatory diseases such as ankylosing
spondylitis,[7] rheumatoid arthritis,[8] and Behçet’s disease.[9]
In the present study, we examined the effect of carrier status of HLA-B and-DRB1 alleles on
FMF by the comparison of the frequencies between patients and non-disease control individu-
als by employing the probands of FMF pedigree and sporadic FMF cases who were captured by
our previous national surveillance study.[6] HLA effects on clinical forms of FMF, subsets of




Blood samples were donated by the probands of FMF pedigree or sporadic cases of FMF, who
satisfied the modified Tel-Hashomer criteria for FMF with either “typical” or “incomplete” at-
tacks,[10] after the acquisition of written informed consent from each patient. Information
about clinical feature was reported by health care providers participated to national surveil-
lance study in Japan as reported previously;[6] in brief, epidemiological data (including gender,
HLA Polymorphisms in Japanese FMF
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consanguinity of parents, familial history and age of onset of inflammation signs) and major
clinical data (including fever, thoracic, abdominal, articular, cutaneous signs, duration and fre-
quency of episodes, presence of amyloidosis, and response to colchicine) were provided by a
standard form. Differential diagnosis between typical and incomplete attacks was made accord-
ing to the following criteria: a typical FMF attack is defined as 3 or more episodes of generalized
peritonitis, or monoarthritis of the hip, knee or ankle lasting 12 hours to 3 days with a fever of
38°C or more, while an incomplete attack is defined as a fever less than 38°C of ill-defined du-
ration (from 6 hours to 1 week), no sign of peritonitis or localized abdominal sign during ab-
dominal attack and atypical distribution of arthritis.[6] Genotype ofMEFV was determined
during a diagnostic procedure;[6] E84K, L110P, E148Q, R202Q, E225K, G304R, R354Q,
P369S, R408Q, R410H, S503C, M694I and P751L were identified. All the study procedures
were approved by institutional review boards of National Hospital Organization Nagasaki
Medical Center and Nagasaki University.
HLA-B and -DRB1 genotyping
DNA was extracted from the blood sample and subjected to HLA-B and-DRB1 genotype deter-
mination by WAKFlow HLA typing kit (Wakunaga Pharmaceutical, Osaka, Japan) based on
the reverse sequence-specific oligonucleotide probes method coupled with xMAP technology
designed for use with the Luminex system (Luminex Japan, Tokyo, Japan).
Statistics
The risk/protective effects of carrier status ofHLA alleles were evaluated by odds ratio (OR) ob-
tained by the comparison of frequencies between patients and controls.HLA genotype data of
299 healthy volunteers, who were staff of National Hospitals, were used as controls in the pres-
ent study. Independency or interaction between HLA factors was assessed by subgroup analysis
after the stratification by carrier status ofHLA alleles of interest. Further, the HLA effect on the
responsiveness to colchicine treatment was evaluated by the comparison ofHLA carrier status
between poor responders and responders. All the statistical analyses were performed using
STATA12 (StataCorp, College Station, TX, USA).
Results
Clinical feature of patients with FMF
Two hundred fifty eight mutually unrelated patients with FMF were enrolled in the present
study. Among them, 149 met the criteria for “typical” FMF (FMF with typical attacks) and the
other 109 were classified as “incomplete” FMF patients (patients with incomplete FMF at-
tacks).MEFVM694I was carried by 85 FMF patients (32.9%) and 159 patients (61.6%) pos-
sessed two copies ofMEFV sequences with detectable pathological mutations (Table 1). In
accordance with our previous report, [6] almost all patients carryingMEFVM694I (98.8%) ex-
hibited clinical features of “typical” FMF (Table 1)
Effect of HLA-B and-DRB1 on the risk of FMF
Fourteen HLA-B alleles (B07:02, B15:01, B35:01, B39:01, B40:01, B40:02, B40:06,
B44:03, B46:01, B48:01, B51:01, B52:01, B54:01 and B55:02) and 13HLA-DRB1 alleles
(DRB101:01, DRB115:01, DRB115:02, DRB104:03, DRB104:05, DRB104:06, DRB104:10,
DRB112:01, DRB113:02, DRB114:54, DRB108:02, DRB108:03 and DRB109:01) were pos-
sessed by 5% or more of the patients or controls. Carriers of B15:18 occupied more than 5% of
typical FMF. These alleles were examined whether the carrier frequencies were different
HLA Polymorphisms in Japanese FMF
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between patients and controls. Consequently, 4 HLA-B (B39:01, B52:01, B40:01 and
B44:03) and 3 HLA-DRB1 (DRB115:02, DRB104:03 and DRB108:02) alleles were signifi-
cantly different (Table 2 and S1 Table). The carriers of B39:01 were increased in the patients
(OR = 3.25, p = 0.0012), whereas those of DRB115:02 were decreased (OR = 0.45,
p = 0.00050), satisfying Bonferroni’s correction for multiple statistical test (n = 28, p<0.00179)
among them.
HLA effects on the clinical forms of FMF andMEFV genotype
Next, theHLA effects were examined for two clinical forms of FMF, typical and incomplete
FMF, as well as patients with certainMEFV genotypes (Table 2). The precipitating effect of
B39:01 was observed in incomplete FMF and patients without high-penetranceMEFV allele
M694I with higher OR and smaller p value than the comparison between FMF and controls
(OR = 4.30 and 3.83, p = 0.00028 and 0.00037, respectively), but not in typical FMF or patients
carrying M694I. In contrast, the protective effect of DRB115:02 was evident in both typical
and incomplete FMF (OR = 0.55 and 0.32, p = 0.025 and 0.0010) and in both carriers and non-
carriers of M694I (OR = 0.47 and 0.42, p = 0.028 and 0.0013), while the effect was slightly
stronger in incomplete FMF and patients without M694I. The major HLA effects were aug-
mented in the patients without canonicalMEFV variant allele M694I, in accordance with the
notion that the lower penetrance in the subset of the disease is owing to the larger contribution
of modifiers in the pathogenesis. Additional precipitating alleles such as B40:01, B15:18,
B15:01, DRB104:03 and DRB108:02 were significant in typical FMF, whereas B35:01 and
DRB104:10 were increased only in incomplete FMF.

















Number n = 258 n = 149 n = 109 n = 85 n = 172 n = 159 n = 99
Age of onset (years,
mean±SD)
28.5±18.9 23.6±16.1 35.8±20.6 19.7±12.7 32.9±20.1 26.9±18.2 30.9±20.0




15/98 (15.3%) 25/83 (30.1%) 28/161
(17.4%)




- - 84/85 (98.8%) 64/172
(37.2%)
104/159 (65.4%) 45/99 (45.5%)
Incomplete FMF 76/225
(33.8%)
- - 1/85 (1.2%) 108/172
(62.8%)




































† Patients with FMF were stratified in two ways according to MEFV genotype; (i) presence/absence of a canonical mutation M694I and (ii) homozygosity
(homo), compound heterozygosity (compound het) or hemizygosity (hemi) in terms of detectable pathological mutations.
doi:10.1371/journal.pone.0125938.t001
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Interaction between HLA alleles
Independence/interaction of HLA factors was evaluated by the comparison of carrier frequen-
cies between subpopulations of patients and controls after stratification by carrier status of an-
other HLA allele of interest. Mantel-Haenszel weighed mean was adopted to estimate an OR
for each of 4 HLA-B and 3 HLA-DRB1 significant alleles adjusted for carrier status of the other
6 HLA alleles (Table 3). Among 42 estimations, only OR of B52:01 adjusted for DRB115:02
and that of DRB115:02 adjusted for B52:01 were profoundly attenuated by adjustment, be-
cause B52:01 and DRB115:02 were associated non-randomly as one of ancestral HLA haplo-
types in the Japanese population.[11] Although it did not reach statistical significance, a point
estimation of OR of DRB115:02 remained less than one regardless of the presence or absence
of B52:01, but not in vice versa (Table 4), suggesting the primary role of DRB115:02 in the
protective effect conferred by the B52:01-DRB115:02 haplotype. Adjusted ORs were similar
to un-adjusted ORs irrespectively of the carrier status of the second HLA allele for the other
combinations, indicating independence of these HLA factors as the modifiers of the disease
risk except for B52:01. Further, the unexpected interaction between B40:01 and DRB115:02
was also demonstrated by stratification analysis, in which the protective effect of DRB115:02
was completely disabled in the presence of B40:01 (Table 4).
Table 2. HLA carrier status in the patients with FMF.
HLA allele All patients Clinical form MFFV genotype







































0.93) p = 0.025
ns ns ns ns ns








B*15:01 ns 1.86 (1.03–
3.35) p = 0.036
ns ns ns ns ns
B*35:01 ns ns 1.92 (1.07–3.42)
p = 0.025
ns ns ns ns


























5.39) p = 0.018





DRB1*04:10 ns ns 2.75 (1.20–6.28)
p = 0.012
ns ns ns 2.78 (1.19–6.48)
p = 0.013
Odds ratio and its 95% confidence intervals (in parenthesis) for the carriers of HLA-B and-DRB1 alleles were listed when the comparison with the controls
gave p<0.05. The results which remained significant after the Bonferroni’s procedure are highlighted in bold with their p values: 15 HLA-B and 13 DRB1
alleles, in total 28 HLA allele carriers were tested because their frequencies in patents and/or controls were 5% or more; p<0.05/280.00179. ns: not
significant, (p  0.05).
doi:10.1371/journal.pone.0125938.t002
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Response to colchicine treatment
Although the good response to the treatment with oral colchicine administration is one of diag-
nostic criteria for FMF,[10] a relatively small but not negligible part of the patients are resistant
to colchicine-treatment and require alternative anti-inflammatory treatment. Among 170 pa-
tients whose clinical data for the response to colchicine were available, 14 patients (8.2%) were
clinically classified as non-responders to colchicine-treatment. When theHLA alleles significant-
ly associated with FMF, clinical forms of FMF or subgroups of the patients with characteristic
MEFV genotypes identified above were analyzed (Table 5), B35:01 carriers were more likely re-
sistant to colchicine-treatment; 42.9% of 14 treatment-resistant patients and 13.5% of 156 colchi-
cine-responders possessed B35:01 allele (OR = 4.82, 95% confidence interval of OR: 1.47–15.8,
p = 0.0041), satisfying Bonferroni’s collection for multiple statistical tests (n = 11, p<0.0045).
Discussion
Similarity to other inflammatory diseases with respect to HLA-disease
association and differential effects of HLA classes
As an attempt to identify a modifier gene of FMF, we analyze polymorphisms in the HLA-B
and-DRB1 loci because of their possible roles in the determination of antigen specificity in im-
mune response as well as known association with various health conditions including
Table 3. Odds ratio adjusted for carrier status of secondHLA allele.
HLA allele un-adjusted adjusted for





















































































































6.86) p = 0.027
na 2.87 (1.19–

















4.23) p = 0.035
2.12 (1.06–
4.26) p = 0.029
na
Odds ratio (and its 95% confidence intervals) for the carriers of HLA-B and-DRB1 alleles were adjusted for carrier status of those alleles. The results
which remained significant after the Bonferroni’s procedure are highlighted in bold with their p values; p<0.05/280.00179. na: not applicable. ns: not
significant, (p  0.05).
† Because B*52:01 and DRB1*15:02 are in strong linkage disequilibrium in the Japanese population, statistical significance of these tests was
severely attenuated.
doi:10.1371/journal.pone.0125938.t003
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Table 4. Interaction between HLA alleles.
HLA allele / Subpopulation† odds ratio p test for homogeneity‡
B*52:01
DRB1*15:02-negative 0.91 (0.36–2.28) ns (p = 0.84)
DRB1*15:02-positive 1.36 (0.26–7.22) ns (p = 0.71) ns (p = 0.67)
Mantel-Haenszel estimate controlling for DRB1*15:02 1.00 (0.45–2.24) ns (p = 0.99)
B*40:01-negative 0.50 (0.32–0.79) p = 0.0024
B*40:01-positive 1.47 (0.25–8.57) ns (p = 0.67) ns (p = 0.23)
Mantel-Haenszel estimate controlling for B*40:01 0.54 (0.35–0.83) p = 0.0047
B*40:01
B*52:01-negative 1.86 (1.00–3.50) ns (p = 0.051)
B*52:01-positive 5.44 (0.96–30.8) p = 0.031 ns (p = 0.24)
Mantel-Haenszel estimate controlling for B*52:01 2.12 (1.18–3.82) p = 0.0097
DRB1*15:02-negative 1.69 (0.89–3.21) ns (p = 0.10)
DRB1*15:02-positive 9.80 (1.73–55.4) p = 0.0015 p = 0.043
Mantel-Haenszel estimate controlling for DRB1*15:02 2.19 (1.23–3.88) p = 0.0062
DRB1*15:02
B*52:01-negative 0.34 (0.07–1.69) ns (p = 0.17)
B*52:01-positive 0.51 (0.18–1.39) ns (p = 0.18) ns (p = 0.67)
Mantel-Haenszel estimate controlling for B*52:01 0.44 (0.19–1.05) ns (p = 0.056)
B*40:01-negative 0.38 (0.22–0.63) p = 9.7×10–5
B*40:01-positive 2.20 (0.40–12.2) ns (p = 0.35) p = 0.034
Mantel-Haenszel estimate controlling for B*40:01 0.45 (0.28–0.71) p = 0.00053
† The effect of carrier status of HLA-B and-DRB1 alleles were separately calculated in two subpopulations for different carrier status of the second HLA
allele. Odds ratio and its 95% confidence interval (in parenthesis) are given. Mantel-Haenszel weighed mean was given (as shown as adjusted odds ratio
in Table 3). ns: not significant, (p  0.05).
‡ Test for homogeneity of the effects in two subpopulations. The tests showing differential effects are highlighted in bold.
doi:10.1371/journal.pone.0125938.t004
Table 5. HLA carrier status in the poor-responders to colchicine treatment.
HLA alleles Poor responders Responders OR p
HLA-B n = 14 n = 156
B*39:01 4 (28.6%) 17 (10.9%) 3.27 (0.91–11.8) ns (0.055)
B*52:01 1 (7.1%) 26 (16.7%) 0.38 (0.05–3.11) ns (0.87)
B*40:01 1 (7.1%) 23 (14.7%) 0.44 (0.05–3.60) ns (0.61)
B*44:03 2 (14.3%) 21 (13.5%) 1.07 (0.22–5.15) ns (0.92)
B*15:18 0 (0.0%) 7 (4.5%) 0.69 (0.04–12.7)† ns (0.65)
B*15:01 0 (0.0%) 23 (14.7%) 0.20 (0.01–3.40)† ns (0.12)
B*35:01 6 (42.9%) 19 (13.5%) 4.82 (1.47–15.8) 0.0041
HLA-DRB1 n = 14 n = 155
DRB1*15:02 0 (0.0%) 19 (12.3%) 0.24 (0.01–4.21)† ns (0.17)
DRB1*04:03 0 (0.0%) 11 (7.1%) 0.43 (0.02–7.74)† ns (0.30)
DRB1*08:02 4 (26.7%) 17 (10.9%) 0.92 (0.11–7.67) ns (0.92)
DRB1*04:10 2 (14.3%) 6 (3.9%) 4.14 (0.74–23.2) ns (0.078)
Frequency of which was significantly deviated from that of the controls is highlighted in bold.
† OR was obtained by Haldane’s modifications of Woolf’s formula.
doi:10.1371/journal.pone.0125938.t005
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inflammatory diseases, which share certain clinical features with FMF. Consequently, several
HLA-B and-DRB1 alleles were demonstrated to be associated with FMF; some of them were re-
ported as risk/protective factor for other diseases. B39:01 was associated with severe and sus-
tained osteoarticular manifestations complicated with Brucella infection,[12] and B27-
negative ankylosing spondylitis,[13] suggesting its proinflammatory nature. Indeed, there are
accumulating evidences for special ligand binding characteristics with HLA-B39.[14,15]
B40:01 which encodes HLA-B60 antigenic specificity was the second most significantly associ-
ated HLA-B allele with FMF in the present study and has been identified an additional risk fac-
tor for ankylosing spondylitis also.[16–18] In contrast, apart from their primary function of
antigen presentation to CD4-positive T helper cells in immune response, certain HLA class II
alleles play a role in the protection from autoimmunity as in the case ofDRB113:02 in systemic
lupus erythematosus, rheumatoid arthritis and autoimmune thyroid disease,[19–21] and
DRB115:02 in rheumatoid arthritis without anti-citrullinated peptode/protein antibodies
(ACPA-negative RA),[22] in Japanese for example, although the underlying biological mecha-
nisms remain to be uncovered. Similarly, the biological implication of DRB115:02 in the pro-
tection from FMF is not clear, but non-competitive interaction between B40:01 and
DRB115:02 (Table 4) was distinctive and can provide a potential clue to the understanding of
the contribution of protective HLA in the pathogenesis of FMF.
Common genetic predisposition to FMF and other inflammatory
diseases
It has been reported that the patients with FMF are predisposed to other inflammatory diseases
such as ankylosing spondylitis and Behçet disease.[23,24]MEFVmutations play a role to in-
crease the risk of these diseases even among the patients without the complication of FMF.[25–
28] Although it still remains unclear how the symptoms of periodical fevers of FMF are trig-
gered, theMEFV product interacts with cellular components of inflammasome whose activity
is augmented by the pathogenic mutations.[29] Therefore, it is reasonable to consider that
FMF-associatedMEFVmutations enhance the cellular responses in the inflammatory diseases
which are also associated with certain HLA polymorphisms. Uncovering of the common un-
derlying mechanism in the pathogenesis of these inflammatory diseases in the context of
HLA-MEFV interaction would be helpful to find an effective target of novel therapeutic or
preventive measures.
Predictors of colchicine response
Colchicine is the first choice of the medical treatment of FMF. The response to colchicine is
one of remarkable characteristics of FMF and has been a very effective criterion for the differ-
ential diagnosis FMF from other inflammatory diseases. In the present study, 14 of 170 patients
(8.2%) whose response to colchicine treatment was available were reported as poor responders
by care-providing physicians. It has been widely recognized that 5–15% of the patients with
FMF do not respond to colchicine.[30] We did not examine ABCB1 polymorphisms which are
associated with colchicine non-responders,[31] in the present study, but six HLA-B35:01-car-
riers were identified among poor responders (42.9%) giving a significant increase in the carrier
frequency in comparison to colchicine responders. The positive predictive value of
HLA-B35:01-carriage remained as much as 0.24, but it was a moderately useful predictor of
prognosis as assessed by positive likelihood ratio of 4.35.[32] Despite nation-wide collection of
FMF in Japan, the evaluation of predictors of colchicine response was made with relatively
small number of poor responders only whose clinical documents were available. Therefore the
result of the present study should be confirmed by more colchicine poor responders. None the
HLA Polymorphisms in Japanese FMF
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less for this limitation, combination with other prognostic markers such as ABCB1 SNPs may
improve the accuracy of prediction to meet practical demands.
Conclusions
The differential effects of HLA class I and class II alleles on FMF were identified for Japanese
population. Modifier genes including HLA explain low penetrance of non-canonical mutations
at least in part. Further,HLA-B35:01 can be a useful predictive marker for the failure of
colchicine treatment.
Supporting Information
S1 Table. Frequency of HLA carriers in the patients with FMF. Frequency of which was sig-
nificantly deviated from that of the controls is highlighted in bold. † Patients with FMF were
stratified in two ways according to MEFV genotype; (i) presence/absence of a canonical muta-
tion M694I and (ii) homozygosity (homo), compound heterozygosity (compound het) or
hemizygosity (hemi) in terms of detectable pathological mutations.
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